Background The introduction of biologics into the treatment of psoriatic arthritis (PsA) has dramatically improved clinical outcomes. Across the approximately 2 decades since the first tumor necrosis factor α (TNF-α) inhibitors were approved in the early 2000s, available drug options for patients with PsA have continued to evolve. In particular, biologics targeting the interleukin 17…
Background Psoriatic arthritis (PsA) is a heterogeneous disease with variable phenotypes.1 Several composite measures have been developed in the past decade to assess disease activity in PsA, but there is no consensus on the best method to accurately assess patients’ overall disease activity and responses to treatment.2,3 Recently, the Group for Research and Assessment of…
Abstract/Summary Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi in facilisis libero, eget congue lorem. Nulla non ligula eget erat aliquam lacinia a eget felis. Nulla turpis sapien, ultricies sit amet suscipit quis, auctor id risus. Donec pellentesque tellus metus, in eleifend lacus euismod eget. Vestibulum vehicula ut metus id vestibulum. Nam vulputate sapien…
